The role of trimetazidine in inhibiting cardiomyocyte apoptosis

Archives of Medical Science

Volumn 3, Issue 3 SUPPL. A, 2007, Pages

  Ruixing, Yin ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Mechanism; Myocardium; Trimetazidine

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM; CREATINE KINASE; FATTY ACID; GLUCOSE; OXYGEN RADICAL; SODIUM; TRIMETAZIDINE;

APOPTOSIS; CARDIOTOXICITY; DRUG MECHANISM; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INFLAMMATION; MITOCHONDRION; NEUTROPHIL CHEMOTAXIS; PROTEIN SECRETION; REPERFUSION INJURY; REVIEW;

EID: 38549097298     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74: 86-107.
2. Ruixing Y, Dezhai Y, Jiaquan L. Effects of cardiotrophin-1 on hemodynamics and cardiomyocyte apoptosis in rats with acute myocardial infarction. J Med Invest 2004; 51: 29-37.
3. Ruixing Y, Jie C, Jiaquan L, Dezhai Y. Cardiomyocyte apoptosis and expression of apoptotic genes in acute myocardial infarction of rats. Chin J Geriatr Heart Brain Vessel Dis 2004; 6: 37-40.
4. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996; 148: 141-9.
5. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med 1996; 335: 1190-6.
6. Zhang J, Clark JR Jr, Herman EH, Ferrans VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol 1996; 28: 1931-43.
7. Ruixing Y, Jiaquan L, Jie C, Dezhai Y. Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis. Growth Factors 2006; 24: 209-17.
8. Ruixing Y, Al-Ghazali R, Wenwu L, Jinzhen W. Pretreatment with probucol attenuates cardiomyocyte apoptosis in a rabbit model of ischemia/reperfusion. Scand J Clin Lab Invest 2006; 66: 549-58.
9. Ruixing Y, Dezhai Y, Hai W, Kai H, Xianghong W, Yuming C. Intramyocardial injection of vascular endothelial growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis. Eur J Heart Fail 2007; 9: 343-51.
10. Yin RX, Liang WW, Liu TW, Tao XZ, Zhu LG, Al-Ghazali R. Inhibitory effect of trimetazidine on cardiac myocyte apoptosis in rabbit model of ischemia-reperfusion. Chin Med Sci J 2004; 19: 242.
11. Ruixing Y, Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 2007; 149: 152-60.
12. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.
13. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J 2006; 70: 1169-73.
14. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy - the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12: 35-42.
15. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007; 7: 143-50.
16. Cesar LA, Mathias W Jr, Armaganijan D, et al. Trimetazidine to reverse ischemia in patients with class I or II angina: a randomized, double-blind, placebo-controlled dobutamine-atropine stress echocardiography study. Coron Artery Dis 2007; 18: 259-63.
17. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996; 79: 949-56.
18. Galang N, Sasaki H, Maulik N. Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicology 2000; 148: 111-8.
19. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94: 1621-8.
20. Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 2000; 32: 197-208.
21. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
22. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991; 5: 2529-37.
23. Barsotti A, Di Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion [Italian]. Ital Heart J 2004; 5: 29S-36S.
24. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 1999; 100: 305-11.
25. Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997; 29: 859-70.
26. Wu CF, Bishopric NH, Pratt RE. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 1997; 272: 14860-6.
27. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-35.
28. Sakai S, Miyauchi T, Kobayahi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-5.
29. Mann DL. Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet 1999; 353: 1812-3.
30. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988; 1: 677-86.
31. El Banani H, Bernard M, Baetz D, et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 2000; 47: 688-96.
32. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002; 45: 69-72.
33. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-8.
34. Ikizler M, Dernek S, Sevin B, Kural T. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia. Anadolu Kardiyol Derg 2003; 3: 303-8.
35. Di Pasquale P, Lo Verso P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 1999; 13: 423-8.
36. Spedding M, Tillement JP, Morin D, Le Ridant A. Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine [French]. Therapie 1999; 54: 627-35.
37. Veitch K, Maisin L, Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol 1995; 76: 25B-30B.
38. Argaud L, Gomez L, Gateau-Roesch O, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39: 893-9.
39. Gambert S, Vergely C, Filomenko R, et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 2006; 283: 147-52.
40. Kantor P, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
41. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003; 93: e33-7.
42. Mody FV, Singh BN, Mohiuddin IH, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82 (Suppl): 42K-9K.
43. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148-51.
44. Guarnieri C, Muscari C. Anti oxy-radical properties of trimetazidine. Res Commun Chem Pathol Pharmacol 1989; 64: 215-25.
45. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999; 43: 860-78.
46. Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828-33.
47. Tritto I, Wang P, Kuppusamy P, Giraldez R, Zweier JL, Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 2005; 46: 89-98.
48. Kuralay F, Altekin E, Yazlar AS, Onvural B, Goldeli O. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine. Tohoku J Exp Med 2006; 208: 203-12.
49. Pudil R, Pidrman V, Krejsek J, et al. The effect of trimetazidine on C-reactive protein, cytokines and adhesion molecules in the course of acute myocardial infarction. Acta Medica (Hradec Kralove) 2001; 44: 135-40.
50. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
51. Fragasso G, Piatti Md PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146: E18-E25.
52. Monti LD, Setola E, Fragasso G, et al. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006; 290: E54-E59.
53. Di Napoli P, Chierchia S, Taccardi AA, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16: 228-36.
54. Morgan EE, Young ME, McElfresh TA, et al. Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Fundam Clin Pharmacol 2006; 20: 503-5.
55. Bayram E, Atalay C, Kocaturk H, Yucel O. Effects of trimetazidine on lipid peroxidation, antioxidant enzyme activities and plasma brain natriuretic peptide levels in patients with chronic cor pulmonale. J Int Med Res 2005; 33: 612-9.